Search clinical trials for: ALT-836

Total 255448 results

Altor BioScience
Genentech, Inc.; Tanox

Completed

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

Sepsis | Acute Respiratory Distress Syndrome | Acute Lung Injury

United States, Canada
Altor BioScience
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Sepsis | Acute Respiratory Distress Syndrome | Acute Lung Injury

United States
Arbutus Biopharma Corporation

Terminated

Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

Chronic Hepatitis

Korea, Republic of, Hong Kong, Thailand, Canada, Australia, Moldova, Republic of, New Zealand, Ukraine
Global Alliance for TB Drug Development

Completed

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection

United States
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
DICE Therapeutics, Inc.

Completed

Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants

Healthy Volunteers

Netherlands
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

Hypertension | Dyslipidemias

Korea, Republic of
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
AbbVie (prior sponsor, Abbott)

Completed

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

Type2 Diabetes Mellitus
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar | Senile Lentigo

Georgia
Neurocrine Biosciences
Takeda

Completed

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Healthy Volunteers

United States
Calithera Biosciences, Inc

Completed

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

Healthy Volunteers

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Alopecia | Male Pattern Hair Loss

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

Healthy

United States
AbbVie

Completed

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

Major Depressive Disorder
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-806 in Subjects With Advanced Solid Tumor Types

Advanced Solid Tumors

United States
Chong Kun Dang Pharmaceutical

Completed

A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

Hypertension | Dyslipidemias

Korea, Republic of
NCIC Clinical Trials Group
Cascadian Therapeutics Inc.

Completed

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Glioblastoma

Canada
NCIC Clinical Trials Group
Oncothyreon Canada Inc.

Completed

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

Canada
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Terminated

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Lymphoma

United States
Cascadian Therapeutics Inc.

Completed

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

Healthy Volunteer

United States
TME Pharma AG
Profil Institut für Stoffwechselforschung GmbH

Completed

NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Kallyope Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Obesity | Type 2 Diabetes Mellitus (T2DM)

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
TME Pharma AG

Completed

A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

Renal Impairment

Hungary, Moldova, Republic of
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

Schizophrenia

Japan
Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Active, not recruiting

Phase III Study of KX-826 With Adult Male Patients With AGA

Androgenetic Alopecia

China
Shanghai Zhimeng Biopharma, Inc.

Recruiting

A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China

Healthy Volunteers

China
Amgen

Terminated

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

Diabetes Mellitus

United States
TME Pharma AG

Completed

NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria

Type 2 Diabetes Mellitus | Albuminuria

Poland, Germany, Romania, Hungary, Czech Republic
Virobay Inc.

Completed

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing (VBY036P1B)

Healthy

United States
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Solid Tumor

United States, Italy
Amgen

Terminated

Single Ascending Dose Trial in Patients With Type 2 Diabetes

Diabetes Mellitus

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety, PK and PD Study in Healthy Male Japanese Subjects

Schizophrenia
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating SCA-136 Tolerability With Dose Titration and Food

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

Schizophrenia

United States
NeuroActiva, Inc.

Completed

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Neurocognitive Disorders | Neurodegenerative Diseases | Cognitive Impairment | Alzheimer Disease | Tauopathies | Mild Cognitive Impairment | Dementia, Vascular | Dementia With Lewy Bodies | Alzheimer Dementia | Cognitive Disorder

New Zealand
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Shanghai Zhimeng Biopharma, Inc.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B

Chronic Hepatitis b
Theravance Biopharma

Completed

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Asthma

United Kingdom
Theravance Biopharma

Completed

Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Asthma

United Kingdom
TME Pharma AG

Completed

NOX-E36 First-in-Human (FIH) Study

Type 2 Diabetes Mellitus | Systemic Lupus Erythematosus | Chronic Inflammatory Diseases

Search clinical trials for: ALT-836

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations